Ginger J Gardner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9074737/publications.pdf

Version: 2024-02-01

69 papers	2,220 citations	279798 23 h-index	233421 45 g-index
71 all docs	71 docs citations	71 times ranked	2634 citing authors

#	Article	IF	Citations
1	Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecologic Oncology, 2011, 122, 190-198.	1.4	254
2	Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. Gynecologic Oncology, 2014, 133, 274-277.	1.4	246
3	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic Oncology, 2014, 134, 455-461.	1.4	180
4	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecologic Oncology, 2016, 140, 436-442.	1.4	97
5	The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications. Gynecologic Oncology, 2014, 133, 552-555.	1.4	75
6	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 246-251.	1.4	71
7	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. Annals of Surgical Oncology, 2016, 23, 2522-2528.	1.5	69
8	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. Journal of Clinical Oncology, 2021, 39, 2594-2604.	1.6	66
9	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. Gynecologic Oncology, 2018, 151, 24-31.	1.4	64
10	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecologic Oncology, 2020, 156, 147-153.	1.4	61
11	A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. Gynecologic Oncology, 2016, 142, 139-143.	1.4	57
12	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. Gynecologic Oncology, 2017, 145, 15-20.	1.4	55
13	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. Gynecologic Oncology, 2020, 156, 591-597.	1.4	54
14	Is It Time to Centralize Ovarian Cancer Care in the United States?. Annals of Surgical Oncology, 2016, 23, 989-993.	1.5	44
15	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. Annals of Surgical Oncology, 2016, 23, 2192-2198.	1.5	43
16	A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecologic Oncology, 2017, 145, 230-235.	1.4	43
17	Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. Gynecologic Oncology, 2017, 147, 262-266.	1.4	43
18	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. Gynecologic Oncology, 2016, 142, 217-224.	1.4	42

#	Article	IF	Citations
19	Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy. Gynecologic Oncology, 2014, 132, 102-106.	1.4	40
20	Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecologic Oncology, 2015, 138, 566-572.	1.4	34
21	Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. Gynecologic Oncology, 2017, 146, 263-267.	1.4	33
22	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. Gynecologic Oncology, 2018, 150, 44-49.	1.4	30
23	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. International Journal of Gynecological Cancer, 2020, 30, 1915-1921.	2.5	29
24	Evolution and outcomes of sentinel lymph node mapping in vulvar cancer. International Journal of Gynecological Cancer, 2020, 30, 383-386.	2.5	25
25	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. Gynecologic Oncology, 2019, 154, 77-82.	1.4	24
26	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecologic Oncology, 2019, 154, 144-149.	1.4	24
27	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. Gynecologic Oncology, 2020, 158, 608-613.	1.4	23
28	A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. Supportive Care in Cancer, 2021, 29, 311-322.	2.2	22
29	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. Journal of Gynecologic Oncology, 2020, 31, e17.	2.2	22
30	Risk factors for financial toxicity in patients with gynecologic cancer. American Journal of Obstetrics and Gynecology, 2022, 226, 817.e1-817.e9.	1.3	20
31	Is Robotic-Assisted Surgery Safe in the Elderly Population? An Analysis of Gynecologic Procedures in Patients â‰¥â€‰65ÂYears Old. Annals of Surgical Oncology, 2019, 26, 244-251.	1.5	18
32	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. Gynecologic Oncology, 2021, 163, 36-40.	1.4	18
33	Current and Future Directions of Clinical Trials for Ovarian Cancer. Cancer Control, 2011, 18, 44-51.	1.8	17
34	Abdominal wall endometriosis: differentiation from other masses using CT features. Abdominal Radiology, 2017, 42, 1517-1523.	2.1	16
35	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology, 2018, 151, 433-437.	1.4	16
36	Role of delayed interval debulking for persistent residual disease after more than 5Âcycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecologic Oncology, 2020, 159, 434-441.	1.4	16

#	Article	IF	Citations
37	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. Annals of Surgical Oncology, 2020, 27, 3772-3780.	1.5	16
38	A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors. Gynecologic Oncology, 2020, 158, 366-374.	1.4	15
39	Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. Annals of Surgical Oncology, 2017, 24, 251-256.	1.5	14
40	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. Gynecologic Oncology, 2021, 161, 687-692.	1.4	14
41	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. Gynecologic Oncology, 2016, 143, 496-503.	1.4	12
42	Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology. Annals of Surgical Oncology, 2018, 25, 984-990.	1.5	12
43	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. Gynecologic Oncology, 2020, 159, 66-71.	1.4	12
44	Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic Oncology, 2013, 128, 28-33.	1.4	11
45	Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. Gynecologic Oncology, 2016, 140, 383-386.	1.4	10
46	Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. International Journal of Gynecological Cancer, 2022, 32, 159-164.	2.5	10
47	Ovarian Cancer Cytoreductive Surgery in the Elderly. Current Treatment Options in Oncology, 2009, 10, 171-179.	3.0	9
48	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. Gynecologic Oncology, 2021, 162, 345-352.	1.4	8
49	Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. Scientific Reports, 2022, 12, 974.	3.3	8
50	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. Gynecologic Oncology, 2017, 147, 371-374.	1.4	7
51	State of the science: Evolving role of surgery for the treatment of ovarian cancer. Gynecologic Oncology, 2019, 155, 3-7.	1.4	7
52	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	7
53	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. Gynecologic Oncology, 2020, 158, 397-401.	1.4	7
54	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. Gynecologic Oncology, 2020, 159, 418-425.	1.4	7

#	Article	IF	Citations
55	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. International Journal of Gynecological Cancer, 2020, 30, 1554-1561.	2.5	7
56	CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: A gynecologic oncology group study. Gynecologic Oncology, 2012, 124, 216-220.	1.4	6
57	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. International Journal of Gynecological Cancer, 2020, 30, 1162-1168.	2.5	6
58	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. International Journal of Gynecological Cancer, 2020, 30, 1183-1188.	2.5	4
59	Surveillance patterns of cervical cancer patients treated with conization alone. International Journal of Gynecological Cancer, 2020, 30, 1129-1135.	2.5	3
60	Implementation of Evidence-Based Presurgical Testing Guidelines in Patients Undergoing Ambulatory Surgery for Endometrial Cancer. JCO Oncology Practice, 2022, 18, e219-e224.	2.9	3
61	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. Gynecologic Oncology, 2016, 142, 13-18.	1.4	2
62	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecologic Oncology, 2021, 160, 51-55.	1.4	2
63	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. Gynecologic Oncology, 2021, 160, 696-703.	1.4	2
64	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Gynecologic Oncology, 2021, 161, 521-526.	1.4	2
65	Recurrent Ovarian Cancer â€" Sculpting a Promising Future with Surgery. New England Journal of Medicine, 2021, 385, 2187-2188.	27.0	2
66	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. JCO Clinical Cancer Informatics, 2022, 6, e2100154.	2.1	2
67	Quaternary and beyond cytoreduction: An updated and expanded analysis. Gynecologic Oncology Reports, 2021, 37, 100851.	0.6	1
68	Enhanced PAtient Clinical Streamlining (EPACS): Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. Annals of Surgical Oncology, 2022, 29, 1789-1796.	1.5	1
69	ASO Visual Abstract: Enhanced PAtient Clinical Streamlining (EPACS)â€"Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. Annals of Surgical Oncology, 2022, 29, 1805-1806.	1.5	0